US2022025038A1PendingUtilityA1

Use of a cd6 binding partner and method based thereon

Assignee: BIOCON LTDPriority: Jul 23, 2013Filed: May 4, 2021Published: Jan 27, 2022
Est. expiryJul 23, 2033(~7 yrs left)· nominal 20-yr term from priority
C07K 2317/569A61P 19/02A61P 29/00A61P 37/00A61K 2039/505C07K 16/2896A61P 3/10C07K 2317/76C07K 2317/24C07K 2317/55A61P 17/06C07K 2317/622A61K 39/395A61P 1/04G01N 33/564G01N 2333/7155C07K 16/28A61P 37/02
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.

Claims

exact text as granted — not AI-modified
1 . A method of treating graft-versus-host disease in a subject, the method comprising administering to the subject a binding partner that specifically binds to CD6, wherein the binding partner is a humanized antibody Itolizumab or a functional fragment thereof that specifically binds to D1 of CD6; wherein the subject has an increased number of T helper 17 (Th17) cells when compared to a healthy subject. 
     
     
         2 . The method of  claim 1 , wherein the subject also has an increased number of T helper 1 (Th1) cells when compared to a healthy subject. 
     
     
         3 - 5 . (canceled) 
     
     
         6 . The method of  claim 1 , wherein the humanized antibody is Itolizumab. 
     
     
         7 . The method of  claim 1 , wherein the functional fragment of an antibody is selected from the group consisting of a Fab-fragment and a single-chain variable fragment (scFv). 
     
     
         8 . The method of  claim 1 , wherein the method includes monitoring IL-23R expression on blood cells and/or dendritic cells of the subject. 
     
     
         9 . The method of  claim 1 , wherein the method comprises a reduction of one or more of TNF-alpha, IFN-gamma, IL-17, and IL-17A in a body fluid of the patient. 
     
     
         10 . The method of  claim 1 , wherein the method comprises a reduction of expression of IL-23R on one or more of monocytes, T helper cells and natural killer cells in a body fluid of the patient.

Join the waitlist — get patent alerts

Track US2022025038A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.